Literature DB >> 12812983

Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease.

Elizabeth J Slow1, Jeremy van Raamsdonk, Daniel Rogers, Sarah H Coleman, Rona K Graham, Yu Deng, Rosemary Oh, Nagat Bissada, Sazzad M Hossain, Yu-Zhou Yang, Xiao-Jiang Li, Elizabeth M Simpson, Claire-Anne Gutekunst, Blair R Leavitt, Michael R Hayden.   

Abstract

An expanded CAG repeat is the underlying genetic defect in Huntington disease, a disorder characterized by motor, psychiatric and cognitive deficits and striatal atrophy associated with neuronal loss. An accurate animal model of this disease is crucial for elucidation of the underlying natural history of the illness and also for testing experimental therapeutics. We established a new yeast artificial chromosome (YAC) mouse model of HD with the entire human HD gene containing 128 CAG repeats (YAC128) which develops motor abnormalities and age-dependent brain atrophy including cortical and striatal atrophy associated with striatal neuronal loss. YAC128 mice exhibit initial hyperactivity, followed by the onset of a motor deficit and finally hypokinesis. The motor deficit in the YAC128 mice is highly correlated with striatal neuronal loss, providing a structural correlate for the behavioral changes. The natural history of HD-related changes in the YAC128 mice has been defined, demonstrating the presence of huntingtin inclusions after the onset of behavior and neuropathological changes. The HD-related phenotypes of the YAC128 mice show phenotypic uniformity with low inter-animal variability present, which together with the age-dependent striatal neurodegeneration make it an ideal mouse model for the assessment of neuroprotective and other therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12812983     DOI: 10.1093/hmg/ddg169

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  316 in total

Review 1.  Modeling human neurodegenerative diseases in transgenic systems.

Authors:  Miguel A Gama Sosa; Rita De Gasperi; Gregory A Elder
Journal:  Hum Genet       Date:  2011-12-14       Impact factor: 4.132

2.  Disruption of the nuclear membrane by perinuclear inclusions of mutant huntingtin causes cell-cycle re-entry and striatal cell death in mouse and cell models of Huntington's disease.

Authors:  Kuan-Yu Liu; Yu-Chiau Shyu; Brett A Barbaro; Yuan-Ta Lin; Yijuang Chern; Leslie Michels Thompson; Che-Kun James Shen; J Lawrence Marsh
Journal:  Hum Mol Genet       Date:  2014-11-14       Impact factor: 6.150

Review 3.  Neuroinflammation in Huntington's disease.

Authors:  Thomas Möller
Journal:  J Neural Transm (Vienna)       Date:  2010-06-10       Impact factor: 3.575

4.  A critical window of CAG repeat-length correlates with phenotype severity in the R6/2 mouse model of Huntington's disease.

Authors:  Damian M Cummings; Yasaman Alaghband; Miriam A Hickey; Prasad R Joshi; S Candice Hong; Chunni Zhu; Timothy K Ando; Véronique M André; Carlos Cepeda; Joseph B Watson; Michael S Levine
Journal:  J Neurophysiol       Date:  2011-11-09       Impact factor: 2.714

5.  Differential electrophysiological changes in striatal output neurons in Huntington's disease.

Authors:  Véronique M André; Carlos Cepeda; Yvette E Fisher; My Huynh; Nora Bardakjian; Sumedha Singh; X William Yang; Michael S Levine
Journal:  J Neurosci       Date:  2011-01-26       Impact factor: 6.167

6.  Transgenic mice expressing caspase-6-derived N-terminal fragments of mutant huntingtin develop neurologic abnormalities with predominant cytoplasmic inclusion pathology composed largely of a smaller proteolytic derivative.

Authors:  Andrew T N Tebbenkamp; Cameron Green; Guilian Xu; Eileen M Denovan-Wright; Aaron C Rising; Susan E Fromholt; Hilda H Brown; Debbie Swing; Ronald J Mandel; Lino Tessarollo; David R Borchelt
Journal:  Hum Mol Genet       Date:  2011-04-22       Impact factor: 6.150

Review 7.  Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.

Authors:  David C Butler; Julie A McLear; Anne Messer
Journal:  Prog Neurobiol       Date:  2011-11-18       Impact factor: 11.685

8.  Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of Huntington's disease.

Authors:  Xuesong Chen; Jun Wu; Yuan Luo; Xia Liang; Charlene Supnet; Mee Whi Kim; Gregor P Lotz; Guocheng Yang; Paul J Muchowski; Thomas Kodadek; Ilya Bezprozvanny
Journal:  Chem Biol       Date:  2011-09-23

9.  Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice.

Authors:  Marta Garcia-Miralles; Michal Geva; Jing Ying Tan; Nur Amirah Binte Mohammad Yusof; Yoonjeong Cha; Rebecca Kusko; Liang Juin Tan; Xiaohong Xu; Iris Grossman; Aric Orbach; Michael R Hayden; Mahmoud A Pouladi
Journal:  JCI Insight       Date:  2017-12-07

10.  Tracking brain palmitoylation change: predominance of glial change in a mouse model of Huntington's disease.

Authors:  Junmei Wan; Jeffrey N Savas; Amy F Roth; Shaun S Sanders; Roshni R Singaraja; Michael R Hayden; John R Yates; Nicholas G Davis
Journal:  Chem Biol       Date:  2013-11-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.